Welcome to our dedicated page for Tg Therapeutics SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TG Therapeutics, Inc. (NASDAQ: TGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biopharmaceutical issuer. TG Therapeutics describes itself as a fully integrated, commercial-stage biopharmaceutical company focused on B-cell diseases, with revenue driven largely by BRIUMVI (ublituximab-xiiy), a CD20-targeted monoclonal antibody approved for adults with relapsing forms of multiple sclerosis (RMS).
Through its SEC filings, investors can review how TG Therapeutics reports product revenue, research and development expenses, selling, general and administrative expenses, and net income. Recent Form 8-K filings reference press releases announcing quarterly financial results, including details that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners, as well as license, milestone, royalty, and other revenue.
Stock Titan enhances these filings with AI-powered summaries that help explain the key points in lengthy documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q. These tools can highlight information relevant to TG Therapeutics’ B-cell–focused pipeline, including disclosures on BRIUMVI clinical data, development programs like the ENHANCE trial and subcutaneous ublituximab, and early-stage candidates such as azer-cel.
Users can also track current and historical Form 8-K reports for material events, along with other SEC forms as they become available. Real-time updates from the EDGAR system ensure that new TGTX filings appear promptly, while AI-generated overviews provide context on how each filing relates to TG Therapeutics’ commercialization of BRIUMVI, its clinical development activities in multiple sclerosis and autoimmune disease, and its overall financial condition.
TG Therapeutics files its annual report describing a focused strategy on B‑cell–mediated diseases, led by its approved multiple sclerosis therapy BRIUMVI (ublituximab‑xiiy). BRIUMVI is marketed in the U.S. and, through a commercialization deal with Neuraxpharm, is being rolled out across parts of Europe and other ex‑U.S. territories.
The company highlights long‑term Phase 3 data showing very low annualized relapse rates and stable safety for BRIUMVI, and is running late‑stage programs for a subcutaneous formulation and simplified IV dosing. It is also advancing azer‑cel, an allogeneic CD19 CAR‑T for progressive multiple sclerosis, under an exclusive license from Precision.
TG Therapeutics reports robust intellectual property, including U.S. patent protection on BRIUMVI compositions potentially extending to 2042 and 12 years of U.S. biologic exclusivity from its 2022 approval. The report also notes completion of a $100 million share repurchase program and outlines extensive regulatory, commercialization, financing, manufacturing, and compliance risks inherent to its business.
TG Therapeutics reported strong growth for the fourth quarter and full year 2025, led by BRIUMVI. Q4 2025 total revenue was $192.6 million, including BRIUMVI U.S. net revenue of $182.7 million. Full-year 2025 total revenue reached $616.3 million, with BRIUMVI U.S. net revenue of $594.1 million.
Total 2025 revenue rose sharply from $329.0 million in 2024, and net income increased to $447.2 million from $23.4 million. The company issued 2026 guidance targeting approximately $875–900 million in total global revenue, Q1 2026 BRIUMVI U.S. net product revenue of $185–190 million, and about $350 million in operating expenses plus $100 million in subcutaneous BRIUMVI manufacturing and start-up costs.
TG Therapeutics director Laurence N. Charney reported two bona fide gifts of the company's Common Stock to his children. He gifted 30,000 shares on 01/28/2026 and 13,197 shares on 01/29/2026, both at a reported price of $0 per share.
After these gifts, Charney beneficially owned 192,887 shares and then 179,690 shares of Common Stock, held directly. This amount includes shares of restricted stock that vest over various time periods. The gifts were structured so he does not retain beneficial ownership or pecuniary interest in the transferred shares.
TG Therapeutics, Inc. filed a current report to share that it has released a press release providing preliminary fourth quarter and full year 2025 net product revenue, along with 2026 revenue guidance and anticipated development milestones.
The company furnished this information under a Regulation FD disclosure, attaching the full press release as Exhibit 99.1. The exhibit contains the detailed financial figures and milestone timelines, while the report itself mainly documents that this information has been made publicly available.
TG Therapeutics reported that CEO and director Michael S. Weiss received a grant of 622,000 shares of restricted common stock on January 8, 2026. The shares were granted at a price of $0 per share and are subject to performance-based vesting. They will vest on the first anniversary of the date on which the company’s total shareholder return first exceeds the return of the Nasdaq Biotechnology Index over a 3-, 5-, 7-, or 9-year period. Following this award, Weiss beneficially owned 9,778,086 shares of common stock, including other restricted shares that vest over various time periods.
TG Therapeutics CFO Sean A. Power reported an equity grant. On 01/08/2026 he was awarded 90,000 shares of TG Therapeutics common stock at a price of $0 per share, reported as an acquisition of non-derivative securities.
These are restricted shares, with one quarter scheduled to vest on each of 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030. After this grant, he beneficially owns 798,111 shares of common stock, including restricted shares that vest over various time periods, all held directly.
TG Therapeutics director reports stock sale to cover taxes
A director of TG Therapeutics, Inc. (TGTX), Yann Echelard, reported a sale of company common stock. On 11/24/2025, 5,000 shares of TG Therapeutics common stock were sold at a price of $32.57 per share, as shown in Table I of the filing. The explanation states that these shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations.
After this transaction, Mr. Echelard beneficially owned 223,816 shares of TG Therapeutics common stock in direct form, which includes shares of restricted common stock that vest over various time periods.
TG Therapeutics (TGTX) CEO and director Michael S. Weiss filed a Form 4 reporting non-sale transfers of common stock. On 11/05/2025, he reported a distribution of 3,865,126 shares upon termination of the Michael Sean Weiss 2022 Grantor Retained Annuity Trust to irrevocable trusts for the benefit of his children, and a transfer of 803,717 shares to The Weiss Family and Descendants Trust. Both transactions were coded “G” and priced at $0 per share.
Following these transactions, Mr. Weiss beneficially owned 9,156,086 shares of TG Therapeutics common stock. The filing notes that this total includes shares of restricted stock that vest over various time periods.
TG Therapeutics reported Q3 2025 results highlighted by strong BRIUMVI sales and a large tax benefit. Total revenue was
For the first nine months, total revenue was
The company completed its
TG Therapeutics, Inc. filed a current report to note that it has released its financial results. On November 3, 2025, the company issued a press release covering its results of operations for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1. The information about these quarterly and year-to-date results is being furnished, not filed, which means it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.